Review Article
Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence
Table 2
Antiviral treatment of HCV-associated GN: clinical studies.
| | Authors | SVR | Antiviral therapy, schedule | Reference year |
| | Mazzaro et al. [75] | 14% (1/7) | Lymphoblastoid-IFN | 2000 | |
Bruchfeld et al. [76] | 71% (5/7) | IFN-α-2b + ribavirin () | 2003 | | Peg-FN-α-2b + ribavirin () | | Rossi et al. [79] | 100% (3/3) | IFN-α-2b + ribavirin | 2003 | |
Alric et al. [26] | 67% (12/18) | IFN-α + ribavirin () |
2004
| | Peg-FN-α + ribavirin () | | Saadoun et al. [80] | 59% (13/22) | IFN-α-2b + ribavirin () | 2006 | | Peg-FN-α-2b + ribavirin () | |
Roccatello et al. [70] | 11% (6/55) | IFN () | 2007 | | IFN + ribavirin | |
Garini et al. [77] | 75% (3/4) | IFN-α + ribavirin | 2007 | | Peg-FN-α-2a + ribavirin | | Abbas et al. [78] | 13% (4/30) | IFN-α + ribavirin | 2008 | | Saadoun et al. [84] | 40% (4/10) | Peg-IFN-α-2b + ribavirin | 2010 | |
Fabrizi et al. | 0.42 (95% CI, 0.24; 0.61) | Pooled analysis | 2012 |
|
|
Results have been calculated according to an intention-to-treat (ITT) analysis.
SVR: sustained virological response.
|
